Visceral leishmaniasis in a patient with ulcerative colitis: A case report
Introduction. There is a rise of visceral leishmaniasis in immunocompromised patients due to increased availability of immunomodulatory drugs. In order to point at the occurrence of visceral leishmaniasis in patients with inflammatory bowel disease (IBD), we reported a case of female patient with a...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Military Health Department, Ministry of Defance, Serbia
2020-01-01
|
Series: | Vojnosanitetski Pregled |
Subjects: | |
Online Access: | http://www.doiserbia.nb.rs/img/doi/0042-8450/2020/0042-84501800076J.pdf |
id |
doaj-312c9e45c7f44945a829953857cbb440 |
---|---|
record_format |
Article |
spelling |
doaj-312c9e45c7f44945a829953857cbb4402020-11-25T03:10:02ZengMilitary Health Department, Ministry of Defance, SerbiaVojnosanitetski Pregled0042-84502406-07202020-01-0177443543910.2298/VSP180302076J0042-84501800076JVisceral leishmaniasis in a patient with ulcerative colitis: A case reportJanković Goran0Martinović Lena1Dakić Zorica2Mijač Dragana3Štulić Miloš4Krstić Miodrag5Clinical Center of Serbia, Clinic for Gastroenterology and Hepatology, Belgrade, Serbia + University of Belgrade, Faculty of Medicine, Belgrade, SerbiaClinical Center of Serbia, Clinic for Gastroenterology and Hepatology, Belgrade, Serbia + University of Belgrade, Faculty of Medicine, Belgrade, SerbiaUniversity of Belgrade, Faculty of Medicine, Belgrade, Serbia + University of Belgrade, Faculty of Medicine, Department of Microbiology, Belgrade, SerbiaClinical Center of Serbia, Clinic for Gastroenterology and Hepatology, Belgrade, Serbia + University of Belgrade, Faculty of Medicine, Belgrade, SerbiaClinical Center of Serbia, Clinic for Gastroenterology and Hepatology, Belgrade, Serbia + University of Belgrade, Faculty of Medicine, Belgrade, SerbiaClinical Center of Serbia, Clinic for Gastroenterology and Hepatology, Belgrade, Serbia + University of Belgrade, Faculty of Medicine, Belgrade, SerbiaIntroduction. There is a rise of visceral leishmaniasis in immunocompromised patients due to increased availability of immunomodulatory drugs. In order to point at the occurrence of visceral leishmaniasis in patients with inflammatory bowel disease (IBD), we reported a case of female patient with a travel history to European Mediterranean countries, who was on immunosuppressive treatment due to ulcerative colitis. Case report. A 29-year-old female patient was admitted to hospital due to severe relapse of ulcerative colitis. Corticosteroid therapy was administered in addition to previous longterm azathioprine, with clinical response to the treatment. During the course of the disease she had recurrent high-grade fever with marked hepatosplenomegaly and pancytopenia. The diagnosis of leishmaniasis was established by positive serology tests and microscopic finding of amastigotes in bone marrow smears. The disseminated infection was responsive to treatment with liposomal amphotericin B, but therapy had to be discontinued due to urticarial rush. Subsequent therapy with antimony was administered, but it had to be stopped too due to liver toxicity. No further treatment for leishmaniasis was initiated as the clinical and laboratory data suggested that the patient had responded to the treatment. She was discharged from hospital in IBD remission and without signs of the infection. Conclusion. Visceral leishmaniasis should be considered in IBD patients with fever of unknown origin and relevant travel history in order to achieve favorable disease outcome.http://www.doiserbia.nb.rs/img/doi/0042-8450/2020/0042-84501800076J.pdfcolitis, ulcerativediagnosisimmunosuppressive agentsleishmaniasisrisk assessmentserology |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Janković Goran Martinović Lena Dakić Zorica Mijač Dragana Štulić Miloš Krstić Miodrag |
spellingShingle |
Janković Goran Martinović Lena Dakić Zorica Mijač Dragana Štulić Miloš Krstić Miodrag Visceral leishmaniasis in a patient with ulcerative colitis: A case report Vojnosanitetski Pregled colitis, ulcerative diagnosis immunosuppressive agents leishmaniasis risk assessment serology |
author_facet |
Janković Goran Martinović Lena Dakić Zorica Mijač Dragana Štulić Miloš Krstić Miodrag |
author_sort |
Janković Goran |
title |
Visceral leishmaniasis in a patient with ulcerative colitis: A case report |
title_short |
Visceral leishmaniasis in a patient with ulcerative colitis: A case report |
title_full |
Visceral leishmaniasis in a patient with ulcerative colitis: A case report |
title_fullStr |
Visceral leishmaniasis in a patient with ulcerative colitis: A case report |
title_full_unstemmed |
Visceral leishmaniasis in a patient with ulcerative colitis: A case report |
title_sort |
visceral leishmaniasis in a patient with ulcerative colitis: a case report |
publisher |
Military Health Department, Ministry of Defance, Serbia |
series |
Vojnosanitetski Pregled |
issn |
0042-8450 2406-0720 |
publishDate |
2020-01-01 |
description |
Introduction. There is a rise of visceral leishmaniasis in immunocompromised patients due to increased availability of immunomodulatory drugs. In order to point at the occurrence of visceral leishmaniasis in patients with inflammatory bowel disease (IBD), we reported a case of female patient with a travel history to European Mediterranean countries, who was on immunosuppressive treatment due to ulcerative colitis. Case report. A 29-year-old female patient was admitted to hospital due to severe relapse of ulcerative colitis. Corticosteroid therapy was administered in addition to previous longterm azathioprine, with clinical response to the treatment. During the course of the disease she had recurrent high-grade fever with marked hepatosplenomegaly and pancytopenia. The diagnosis of leishmaniasis was established by positive serology tests and microscopic finding of amastigotes in bone marrow smears. The disseminated infection was responsive to treatment with liposomal amphotericin B, but therapy had to be discontinued due to urticarial rush. Subsequent therapy with antimony was administered, but it had to be stopped too due to liver toxicity. No further treatment for leishmaniasis was initiated as the clinical and laboratory data suggested that the patient had responded to the treatment. She was discharged from hospital in IBD remission and without signs of the infection. Conclusion. Visceral leishmaniasis should be considered in IBD patients with fever of unknown origin and relevant travel history in order to achieve favorable disease outcome. |
topic |
colitis, ulcerative diagnosis immunosuppressive agents leishmaniasis risk assessment serology |
url |
http://www.doiserbia.nb.rs/img/doi/0042-8450/2020/0042-84501800076J.pdf |
work_keys_str_mv |
AT jankovicgoran visceralleishmaniasisinapatientwithulcerativecolitisacasereport AT martinoviclena visceralleishmaniasisinapatientwithulcerativecolitisacasereport AT dakiczorica visceralleishmaniasisinapatientwithulcerativecolitisacasereport AT mijacdragana visceralleishmaniasisinapatientwithulcerativecolitisacasereport AT stulicmilos visceralleishmaniasisinapatientwithulcerativecolitisacasereport AT krsticmiodrag visceralleishmaniasisinapatientwithulcerativecolitisacasereport |
_version_ |
1724661031631847424 |